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ABSTRACT 
Background  
 Diabetes Mellitus has become a global epidemic affecting a large group 
of Indian population . Diabetic Peripheral Neuropathy is the commonest 
symptomatic complication of Diabetes . In recent studies it is being estimated 
that the prevalence of Peripheral Neuropathy is equally distributed in Diabetic 
and pre-diabetic population . Since peripheral neuropathy has devastating 
consequences on the morbidity and mortality of a diabetic individual as well as 
in those who are at risk to develop diabetes it is prudent to screen for the 
presence of peripheral neuropathy and its risk factors at an early stage.  
Aim 
 To estimate the prevalence of Diabetic Peripheral Neuropathy in 
subjects with Pre-Diabetes . 
 To Study the distribution of risk factors for Diabetic Peripheral 
Neuropathy in Pre-diabetic subjects.  
Methods 
 After prior Institutional Ethical clearance and obtaining informed 
consent, the participants satisfying inclusion criteria were asked detailed 
history  and clinical examination was performed according to the well designed 
proforma cited below . Venous blood was drawn for fasting blood glucose 
levels, HbA1c levels , serum cholesterol and triglycerides. Height , weight and 
  
waist circumference of the individual patient was measured and BMI was 
calculated . Presence of peripheral neuropathy was assessed by validated MNSI 
(Michigan Neuropathy Screening Instrument ) scoring system. 
Results 
The mean age of the study subjects was 56.3 years . Most of the patients 
belonged to the age group 50-59 years.Out of 216 cases , 110 (50.93%) were 
male and 106 (49.07%) were female. Male to female ratio was 1.04 :1.The 
prevalence of Diabetic peripheral neuropathy in the study population was 
28.24%. The prevalence of Systemic Hypertension in subjects with DPN was 
52.5 %.The average BMI of the study population was 24.2 %.The average 
HbA1c of the study population was 5.8 %. Most of the subjects with DPN 
belonged to the group where the HbA1c levels were between 6.1-6.4 %. The 
prevalence of DPN subjects with HbA1c ≥6.1 was 59.02 %.The prevalence of 
hypercholesterolemia in the study population was 22.2 percent. Mean 
cholesterol level of the subjects with peripheral neuropathy was 214.75 mg/dl. 
The prevalence of hypercholesterolemia in patients with Peripheral Neuropathy 
was 63.9 percent. The prevalence of hypertriglyceridemia in the study 
population was 14.4 % . The mean TGL of the study population was 135.11 
mg/dl. Mean TGL levels in subjects with DPN was 146.95 mg/dl and in 
subjects without DPN was 130.45 mg/dl. The prevalence of 
hypertriglyceridemia in peripheral neuropathy was 37.7 percent. The 
prevalence of smokers in the study population was 16.2 % .The prevalence of 
smokers in DPN was 27.87%. The average waist circumference of the study 
  
population was 82.58 cms. The prevalence of abnormal waist circumference in 
subjects with peripheral neuropathy was 52.46 % 
Conclusion 
 The prevalence of DPN in the study population was 28.24 %. The 
prevalence of risk factors such as increased age, hypertension, smoking , 
obesity, dyslipidemia, higher HbA1c levels were significantly higher in pre-
diabetic population who had peripheral neuropathy.  Since the prevalence of 
peripheral neuropathy is high even in pre-diabetic population , my study 
emphasises the need for the early diagnosis of peripheral neuropathy in 
people who are at high risk for developing diabetes and to screen for the 
possible associated risk factors 
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INTRODUCTION 
Diabetes Mellitus has become a global epidemic affecting not only 
Western population, but also the Asian population including those of the Indian 
citizen.  There are currently an estimated number of more than 62,000,000 
people suffering from this disease in India. The prevalence of prediabetic 
population is even higher with estimated 77.2 million people in the year 2011 
by Indian Council of Medical Research census.1  By the year 2030 it is 
estimated that there will be nearly 80 million Indians with Diabetes . It is 
associated with more than two fold excess mortality from cardiovascular 
disease, devastating microvascular complication affecting the eyes, kidneys and 
nerves as well as comorbidity including cancer, infection and psychosocial 
stress. 
 
 Diabetic Peripheral Neuropathy (DPN) is the commonest symptomatic 
complication of Diabetes.2 Prevalence of Diabetic peripheral Neuropathy is 15 
to 40 percent in various study groups.3It predisposes to foot ulceration and 
gangrene. Type 2 Diabetes Mellitus is characterised by long asymptomatic 
phase ( ranges from 4 to 7 years) between the actual onset of hyperglycemia 
and clinical diagnosis which may explain the relatively high prevalence of 
microvascular complication in newly diagnosed patients with Type Diabetes 
Mellitus. In view of poor awareness and lack of regular screening programmes, 
the initial presentation to the physicians is delayed frequently. This may 
predispose to increased rate of microvascular complication at onset. 
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There is an emerging evidence that Peripheral Neuropathy begins in the 
early stages of Diabetes pathogenesis . Hence this study aims to estimate the 
prevalence of peripheral neuropathy and its risk factors in prediabetic 
population attending the outpatient department of Government Vellore Medical 
College Hospital during the period between September 2015 to August 2016 . 
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AIM OF THE STUDY 
1. To estimate the prevalence of Diabetic Peripheral Neuropathy in 
subjects with Pre-diabetes. 
 
2. To study the distribution of risk factors for Diabetic Peripheral 
Neuropathy in Pre-diabetic subjects . 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW 
 
Diabetes mellitus has been described in various documentation dating 
centuries back . According to Tattersal Diabetes was first recognised and 
documented in the Egyptian ancient Papyrus in 1550 bc over 3500 years ago.6 
 
However the historians believed that Cornelius Celsus (30BC-50AD) of 
Greece was the one to enumerate the symptoms which was thought to be 
similar to that of Diabetes. He described a dreadful condition presenting as 
excessive urine production and emaciation . 
 
 The term “ Diabetes “ is a Greek word which means “ run through or 
siphon” which was ascribed to Demetrios of Apamaia dated back to 200-250 
BC. Later few few centuries later in 130 AD, Aretaeus of Cappadocia 
reintroduced the forementioned word to describe the disease causing wasting 
from excessive passing of urine. Towards the end of the seventeenth century, 
Johann Brunner (1653-1727) experimented with partial pancreatectomy of dogs 
and found that they had increased thirst , polyphagia and urination thereby 
discovering the role of pancreas in the pathogenesis of Diabetes. In 1798, 
Edinburgh trained surgeon of the British Army John Rollo (1749-1809) added 
the suffix “ Mellitus” meaning honey owing to sweetness of the urine from the 
affected patients. 
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Eventhough it was believed John Rollo was the earliest pioneer in 
describing diabetic Neuropathy , it was Marchal de Calvi back in 1864 who 
associated neuropathy to Diabetes Mellitus in 1864.7 A great insight to the 
classification , clinical manifestation and diagnosis was provided by two 
eminent people Jordan (1936) and Rundles (1945) in the first half of 20th 
century . Jordan emphasized on new classification and reported the natural 
history and prognosis of neuropathy . Rundles focused on describing 
autonomic neuropathy .4,5 
 
DIABETES MELLITUS  
 Diabetes Mellitus is a group of metabolic diseases characterised by 
hyperglycemia which is due either to defect in insulin secretion, insulin action 
or both. 
 There are two major pathological process associated with most of the 
diabetic patient. One is due to destruction of the Beta cells of the pancreas by 
autoimmune process resulting in insulin deficiency .the other process is due to 
resistance to the action of insulin. Diabetic patients have symptoms which 
include polyuria, polydipsia, weight loss, polyphagia and blurred vision. These 
patient have impairement in growth and are susceptible to certain infections 
which occurs  mostly in chronic hyperglycemia. 
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ETIOLOGICAL CLASSIFICATION OF DIABETES MELLITUS8 
1. Type 1 Diabetes  
a. Immune mediated  
b. Idiopathic 
 
2. Type 2 Diabetes  
 
3. Other specific types 
 
 
i. Genetic defects of beta cell dysfunction 
1. MODY 3 
2. MODY 1  
3. MODY 2 
4. Other very rare forms of MODY 
5. Transient neonatal Diabetes 
6. Permanent neonatal Diabetes 
7. Mitochondrial DNA 
8. Others  
 
ii. Genetic defects in insulin action  
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
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4. Lipoatrophic diabetes 
5. Others. 
 
iii. Disease of the exocrine pancreas 
1. Pancreatitis 
2. Trauma/pancreatectomy 
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalculouspancreatopathy 
7. Others 
 
iv. Endocrinopathies 
1. Acromegaly 
2. Cushing’s syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
8. Others 
v. Drugs or Chemical induced- vacor, pentamidine, nicotinic 
acid , glucocorticoids, thyroid hormones, diazoxide, beta 
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adrenergic agonists, thiazides, dilantin, gamma interferon, 
others. 
vi. Infections – congenital rubella, cytomegalovirus, others 
vii. Uncommon forms of immune mediated diabetes – Stiff- 
man syndrome , anti-insulin receptor antibodies, others. 
viii. Other genetic syndromes sometimes associated with 
diabetes – Down syndrome, Klinefelter syndrome, turner 
syndrome, Wolfram syndrome, Friedreich ataxia 
,Huntington chorea, Laurence-Moon-Biedl syndrome, 
Porphyria , prader-Willi syndrome, others. 
 
4. Gestational Diabetes Mellitus 
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DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS8 
 The criteria for diagnosis of diabetes are shown in the table: 
CRITERIA FOR THE DIAGNOSIS OF DIABETES 
A1C ≥ 6.5%. The test should be performed in a laboratory using a method that 
is NGSP certified and standardised to the DCCT assay . 
 
OR 
FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at 
least 8h 
OR 
Two hour plasma glucose ≥ 200mg/dL (11.1mmol/L) during an OGTT. The test 
should be performed as described by the World Health Organisation, using a 
glucose load containing the equivalent of 75 g anhydrous glucose dissolved in 
water. 
OR 
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a 
random plasma glucose ≥ 200 mg /dL (11.1 mmol/L) 
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COMPLICATIONS OF DIABETES 
 Diabetes Mellitus has several complications which are grossly classified 
into either acute or long term complication  
Acute 
 Diabetic Ketoacidosis 
 Hyperglycemic Hyperosmolar state 
 Hypoglycemia 
Long term  
 Retinopathy 
 Neuropathy 
 Nephropathy 
 Ischaemic Heart Disease 
 Cerebrovascular Disease 
 Peripheral Vascular disease 
Others 
 Infections  
o UTI 
o Tuberculosis 
o Candidiasis- Oral/ Vulvovaginal 
o Mucormycosis 
o Necrotising fasciitis 
11 
 
o Periodontitis 
Microvascular complications in Diabetes Mellitus: 
 Microvascular complications of Diabetes involves retina, renal 
glomerulus and nerves of the peripheral nervous system. The complications are 
mainly due hyperglycemia, a relative or total depletion of insulin or due to 
resistance of insulin at the target organ level. 
Pathogenesis 
 The pathogenetic mechanism of microvascular and macrovascular injury 
are different. From various studies it has been deduced that hyperglycemia is 
the main reason behind microvascular injury, whereas insulin resistance is the 
major cause for macrovascular injury . The pathological changes following 
macrovascular injury includes atherosclerosis of arteries. 
 
Mechanism of Microvascular complications:9 
 Most of the cells of our body are able to maintain a constant internal 
milieu of glucose concentration even if they are exposed to high concentration 
by effective transport system . In contrast, the cells damaged by hyperglycemia 
are loose this potential and are exposed to the deleterious effects of high 
glucose. Microvascular injury selectively involves cells like endothelial cells 
and mesangial cells. 
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1. Myoinositol Metabolism: 
Glucose is the only source of energy for organs like brain and its 
connections including peripheral nerves. The mode of entry is through non 
insulin dependent pathways and is used in the production of ATP. Eventhough, 
ATP production is not impaired, experimental diabetic nerves have 
demonstrated reduced utilization of ATP. It is hypothesised to be due to 
decrease Na/K ATPase activity . This decrease in Na/K ATPase activity has led 
to the decrease in myoinositol concentrations in the peripheral nerves of 
diabetic animals. 
 Myoinositol is similar to glucose in structure and is a normal dietary 
constituent. It forms an important component of phospholipid bilayer and cell 
membrane and is 90 to 100 times more concentrated in peripheral nerves than 
in plasma. 
14 
 
 
 
As a result of hyperglycemia there is competitive inhibition of the sodium-
dependant transport system responsible for myoinositol uptake. This results in 
reduced concentration of myoinositol inside the peripheral nerve and decreased 
Na/K ATPase activity .impairment of Na/K ATPase activity has two 
consequences ; reduced nerve cell  membrane potential which inturn decreases 
nerve conduction velocity and reduced myoinositol uptake creating worsening 
vicious cycle .  
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Increased flux through the polyolpathway : 
 
 
 
The Polyol pathway is concerned with the enzyme aldose reductase. The 
normal function of aldose reductase in our body is to reduce accumulated toxic 
aldehydes to inactive alcohols. The same enzyme also reduces glucose to 
sorbitol. When there is hyperglycemia the enzyme aldose reductase is activated 
in increased amount to convert glucose into sorbitol. In this reaction NADPH is 
consumed. NADPH is also the essential cofactor for regenerating an important 
intracellular antioxidant, reduced glutathione. Increased utilization of NADPH 
results in decreased production of reduced glutathione thereby subjecting the 
cell to undue levels of intracellular oxidative stress. 
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Intracellular production of Advanced Glycation End Products    
(AGE) and its potential harmful effects  
There are three well defined mechanism through which Advanced 
Glycation End Products (AGE) exert their harmful effects. The first is the 
modification of intracellular proteins including those involving regulation of 
gene transcription 
1. Glycosylated nerve protein- alteration in myelin macrophage interaction 
– segmental demyelination.10 
2. Glycosylated protein in RBC membrane – decreased deformability of 
Red Blood Cell (RBC) – hyperviscosity- tissue hypoxia- nerve 
dysfunction. 
3. Glycosylated Hemoglobin – increased affinity for oxygen – tissue 
hypoxia – nerve dysfunction ( Ditizel and Strandl, 1975). 
Second mechanism involves the diffusion of the AGE precursors out of 
the cell and modifying the extracellular matrix elements. This changes 
the signalling mechanisms between the cell and the extracellular matrix 
resulting in cellular dysfunction. Advanced glycation end products 
modifies the matrix metalloproteinases , causing damage to the nerve 
fibres. 
The third mechanism involves the modification of the circulating 
proteins in the blood especially albumin .These modified circulating 
protein activate the AGE receptors by binding to them, resulting in 
17 
 
production of inflammatory cytokines and growth factors. This inturn 
causes vascular pathology. 
Protein Kinase activation (PKC activation) 
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This is an important intracellular signalling pathway. Protein Kinase C act as 
an important cofactor for various gene expression. Its precursor. 
Diacylglycerol, which is increased during hyperglycemia results in increased 
production of Protein Kinase C and activation of gene responsible for the 
production of endothelin-1 which is a potent vasoconstrictor and decreased 
production of nitric oxide which is a vasodilator. This dysregulation causes 
vasoconstriction of the small vessels and tissue hypoxia thereby injuring the 
nerves. 
 
Increased Hexosamine pathway activity : 
Normally glucose is metabolised through glycolysis into its component 
metabolites. The first two steps involves the ceonversion of glucose to glucose-
6 phosphate , and then to fructose-6 phosphate and so on . When the 
intracellular glucose is raised the fructose-6 phosphate is shunted into another 
pathway involving its conversion into glucosamine-6 phosphate and finally to 
UDP (UridineDiphosphate) N-acetyl glucosamine. This N-acetyl glucosamine 
gets incorporated onto serine and threonine residues of transcription factors 
.over modification by this glucosamine often culminates in pathologic changes 
in gene expression . Increased expression of transforming growth factor beta 1 
and plasminogen activator inhibitor-1 are hazardous to the blood vessel. 
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Increased production of superoxide by the Mitochondria: 
Increased intracellular glucose results in increased activity of TCA 
cycle, which pushes more electron donors like NADH and FADH2. This 
results in increased voltage gradient across the mitochondrial membrane . 
When a critical threshold is reached electron transfer inside complex III is 
blocked causing electrons to back up to coenzyme Q .Ccoenzyme Q transfers 
the electrons to molecular oxygen producing superoxide . 
Mitochondrial overproduction of superoxide activates the major 
pathways of hyperglycemic damage by inhibiting GAPDH. This is the key 
pathway which activates all other pathways . 
Macrovascular Pathogenesis: 
Macrovascular damage caused by hyperglycemia is relatively less as 
compared to microvasculardamage . Insulin resistance is the cornerstone of 
Diabetic macrovasculardamage . It causes increased production of Reactive 
Oxygen Species in endothelial cells by increased flux of Free Fatty Acid and 
oxidation.  
 
DIABETIC NEUROPATHY19,20 
General Consideration 
Diabetic neuropathy is one of the most common microvascular 
complications of Diabetes Mellitus .  Around 30-50 percent of Diabetic 
20 
 
population have clinical manifestation of peripheral neuropathy and it is 
estimated that the prevalence is much more using electro-physiological 
methods .18 Diabetic Peripheral Neuropathy involves both type 1 and type 2 
Diabetes Mellitus. Occurrence of peripheral neuropathy is highly correlated 
with the HbA1c levels.11 
  
There are many types of Diabetic neuropathy . Of these Distal 
symmetrical polyneuropathy (DSPN) is the most common form . 
 
Classification:12,13 
There are various classifications by numerous authors . Few 
authenticated classification systems are highlighted here . 
1. Bruyn and Garland Classification 
I Symmetrical, predominantly sensory, and distal polyneuropathy 
A. Diabetic pseudotabes 
B. Hyperalgesic type 
II.  Asymmetrical, predominantly motor, and often proximal neuropathy 
A. Mononeuropathy 
B. Multiple neuropathy 
C. Autonomic visceral neuropathy 
D. Radiculopathy 
E. Radiculopathy 
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2. Thomas’ Classification 
I. Symmetrical polyneuropathies 
A. Sensory or sensorimotor polyneuropathy 
B. Acute or subacute motor neuropathy 
C. Autonomic neuropathy 
II. Focal and multifocal neuropathies 
A. Cranial neuropathy 
B. Trunk and limb mononeuropathy 
C. Proximal motor neuropathy 
3. Boluton and Ward Classification 
I Mononeuropathy 
 A. Cranial 
 B. Truncal 
 C. Multiple 
II    Polyneuropathy  
A. Acute sensory neuropathy 
B. Chronic sensory neuropathy 
C. Autonomic  
D. Proximal 
E. Truncal motor 
4. Classification by topography 
Somatic Neuropathies 
I. Distal Symmetric Diabetic Neuropathy 
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A. Predominantly sensory  
 Small fibre (pain and temperature sensory function ) 
 Large fibre (Proprioceptive, vibrational, and muscle reflex 
sensory function). 
 Mixed large and small fibre. 
B. Predominantly motor 
 With sensory neuropathy  
 With hypoglycaemia 
II. Proximal Symmetric Diabetic Neuropathy 
III. Asymmetric Diabetic Neuropathy 
A. Predominantly sensory : Intercostal radiculopathy ,truncal 
radiculopathy 
B. Predominantly motor : Cranial neuropathy, Peripheral 
neuropathy ( Median, ulnar, popliteal ) 
C. Proximal neuropathy 
IV. Autonomic Neuropathies 
I. Cardiovascular  
Exercise intolerance,  cardiac denervation syndrome, 
orthostatic dysregulation 
II. Gastrointestinal  
Gastric emptying abnormality, Constipation, Diabetic 
diarrhoea, incontinence 
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III. Genito-urinary  
Bladder dysfunction, sexual dysfunction 
IV. Counter-regulatory 
V. Sudomotor 
 
RISK FACTORS AND ASSOCIATIONS OF DIABETIC 
NEUROPATHY 
 The two most common independent  risk factors for the occurrence of 
diabetic neuropathy are duration of diabetes and glycemic control  . There are 
additional partially independent risk factors in the form of age, increased BMI 
and smoking .16The presence of cardiovascular disease, elevated triglyceride 
levels, hypercholesterolemia and hypertension were closely associated with the 
incidence of neuropathy in diabetic and pre-diabetic individuals. 
The prime risk factor for diabetic neuropathy is increased blood glucose 
levels and poor control . This was substantiated by the fact that annual 
incidence of diabetic neuropathy which was around 2 percent in conventionally 
treated patient dropped significantly to 0.56 percent in intensively treated type 
1 diabetes.15 
Though the duration of Diabetes is an independent risk factor ; its 
association with the prevalence of neuropathy may depend upon the age of the 
patient since age by itself is one of the risk factors. 17 
24 
 
CLINICAL FEATURES OF PERIPHERAL 
NEUROPATHY 
Diabetic Polyneuropathy initially affects the lower limbs . It most 
commonly presents with distal sensory loss and pain . 50 % of patients do not 
give any history of symptoms but are diagnosed objectively to have peripheral 
neuropathy. Hyperasthesia, paresthesia or dysesthesia may occur in any 
combination . 
SYMPTOMS21 
1. Numbness 
2. Tingling sensation 
3. Sharpness 
4. Burning pain 
Pain is usually present at rest and increased in night time . It can be 
acute and chronic as well. When the pain subsides the sensory loss starts. The 
sensory loss usually starts in the feets and progresses gradually upwards. When 
the sensory loss in the lower extremities reaches the mid-calf level , it starts 
appearing the hands . This pattern is called Glove and stocking distribution of 
sensory loss.  
In contrast to Diabetic Polyradiculopathy ,where the symptoms are self 
limited and resolves after 6-12 months, the sensory loss of diabetic 
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polyneuropathy is persists for longer duration and leads to severe disabling 
complications . 
COMPLICATIONS OF DIABETIC  PERIPHERAL 
NEUROPATHY 
Diabetic polyneuropathy is most often insidious in onset and leads to 
formation of ulcers of the foot as well as various muscle and joint disease. 
These is progressive sensory loss which predispose to ulcer formation . Foot 
ulcers are usually of two types. 
1. ACUTE ULCERS – these are secondary to dermal abrasion as a result 
of poorly fitting shoes. 
2. CHRONIC PLANTAR ULCERS – these occurs in the weight bearing 
areas. It is usually due to three common pathogenetic mechanisms 
involving diabetic neuropathy with decreased pain sensation , autonomic 
dysfunction and vascular insufficiency . 
26 
 
 
DIABETIC NEUROPATHIC ARTHROPATHY22 
 Loss of sensation in the joints leads to chronic painless , progressive and 
destructive joint disease.  
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This is commonly called as Charcot’s joints. Similar changes are seen in 
other neurological disease such as Tabes Dorsalis and syringomyelia.  
 
TREATMENT OF DIABETIC PERIPHERAL 
NEUROPATHY 
 
The cornerstone for the treatment of Diabetic Peripheral Neuropathy 
revolves around three aspects 
1. Good glycemic control 
2. Foot care 
3. Treatment of Pain 
GLYCEMIC CONTROL 
 Optimum glucose control is important in preventing the occurrence of 
diabetic neuropathy . In the longitudinal follow up of large Diabetes Control 
and Complication Trial (DCCT) , adequate control of glucose ameliorated the 
onset of neuropathy as well as progression of surrogate electrophysiological 
markers of neuropathy.23 
FOOT CARE 
It’s the duty of the patient and the treating physician to take due notice 
of the presence of dryness, cracks, fissures, plantar callus formation and signs 
of early infection between the toes and around the toe nails. Regular foot 
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examination by the physician is essential to detect early neuropathy and forms 
an essential component of the treatment of diabetes patients. 
 
TREATMENT OF PAIN 
 There are numerous drugs and modalities available in the market to treat 
pain which is usually very disabling in diabetic neuropathy . 
1. Antidepressants – Amitriptyline , duloxetine , venlafaxine  
2. Anticonvulsants – pregabalin ,sodium valproate 
3. Capsaicin cream 
4. Lidocaine patch 
5. Alpha-lipoic acid 
6. Isosorbidedintitrate Topical spray 
7. Transcutaneous Electrical nerve stimulation 
ANTIDEPRESSANTS 
  In a double blind , placebo-controlled , randomised cross over trial, 
amitriptyline and desipramine were effective in reducing the pain associated 
with neuropathy.24 These drugs can be added to anticonvulsants . These drugs 
have frequent anticholinergic side effects . They are contraindicated in cardiac 
disease. Doxepin can be substituted in patients with cardiac disease since this 
tricyclic antidepressant is the least cardiotoxic. 
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ANTICONVULSANTS 
 Pregabalin and older anticonvulsants like Sodium Valproate are 
commonly used in the treatment of pain of diabetic neuropathy .25Pregabalin is 
usually started as 50 mg twice daily and gradually increased to a maximum of 
150 mg (300 mg) twice daily .side effects of pregabalin includes dizziness, 
ataxia, vertigo , sedation . Valproic acid (500-1200 mg daily ) was effective in 
reducing pain in small place-controlled trials. 
 
CAPSAICIN CREAM 
 It is a natural occurring component of hot peppers .it causes local 
depletion of substance P and thereby reduces pain. It is given as a topical cream 
of 0.075 % applied over extremities 4 times a day .common side effects include 
local burning . 
LIDOCAINE PATCH 
 Applying 5 percent lidocaine patches for 18 hrs per day has been 
documented to improve the pain significantly .26 
ALPHA LIPOIC ACID 
 Alpha lipoic acid is a potent antioxidant which is given in an iv 
formulation three times a week for three week .It has been studied in various 
placebo- controlled studies that this powerful antioxidant decreases the 
oxidative stress and improves the underlying pathophysiology of neuropathy .27 
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OPIOIDS 
 Dextromethorphan which is a weak opioid agonist and NMDA 
antagonist was moderately beneficial in a small trial for reducing pain .28 
 Other opioids like tramadol and oxycodone can also be used but the risk 
of abuse and addiction overweighs their use in the treatment of neuropathic 
pain .29 
 
EXAMINATION SCORES FOR DIABETIC NEUROPATHY 14 
 Internationally validated and frequently used scoring systems for 
diabetic neuropathy are the Neuropathy Disability Score (NDS), the Michigan 
Neuropathy Screening Instrument (MNSI) score, the Neuropathy Impairment 
Score in the Lower Limbs (NISLL), various modified NDS scores, and the 
Clinical Examination Score of Valk (CE-V). 
 The NDS is used for neuropathy in general. The score is validated and 
comprehensive but it is very difficult to perform in clinical practice on diabetic 
patients. Proper description on how the test should be performed and 
interpreted is lacking . The NISLL is a the modified version of NDS and is 
specific for distal peripheral neuropathy. The NISLL and the neuropathy 
Deficit Score has not been validated .  Feldman et al. developed a combination 
of 2 scoring systems : the MNSI (symptom and examination ) score and the 
Michigan Diabetic Neuropathy Score . These scores do not have a separate 
examination score as advised by consensus reports. The CE-V is used for 
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examining the sensory functions, tendon reflexes and strength of the muscles in 
lower limb. The scoring systems of Feldman et al. and Valk et al. have been 
validated and are commonly used in clinics.  
Michigan Neuropathy Screening Instrument  
 MNSI scoring system is highly validated and easy to use in clinical 
practice . It is comparable to the Gold standard Nerve Conduction Study and is 
quite used to screen for Diabetic Peripheral Neuropathy since Nerve 
Conduction Study is cumbersome and needs a Specialist in the form of 
Neurologist and a Neurology Lab. It has two components – a history 
questionnaire which is self administered by the patient and the physical 
assessment scoring system .the physical assessment includes inspection of foot 
, vibration sensation , muscle stretch reflex 
And monofilament testing  
For the assessment of foot it should be warm (>30oC) 
I. Foot Inspection 
The feet are inspected for the evidence of excessively dry skin, 
callous formation , fissures , frank ulcerations or deformities. The 
common deformities to look for are hammer toes, flat feet, hallux 
valgus , joint subluxation, prominent metatarsal heads, overlapping 
toes, medial convexity and amputation. 
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II. Vibration Sensation : Vibration sensation is perfomed using 128 Hz 
tuning fork . The great toe should be unsupported and should be 
tested bilaterally . The tuning fork is placed over the dorsum of the 
great toe on the bony prominence of the Distal Interphalangeal Joint 
just proximal to nail bed. Patient whose eyes are closed , will be 
asked to indicate when they can no longer sense the vibration from 
the vibrating tuning fork.  
 
III. Muscle Stretch Reflex 
The ankle reflexes will be examined using an appropriate reflex 
hammer. It is elicited in the sitting position with the foot dependant 
and the patient relaxed. For the reflex, the foot should be passively 
dorsiflexed to obtain optimum reflex. The Achilles tendon should be 
percussed directly . If the reflex is obtained it is graded as present . If 
the reflex is absent, the patient is asked to perform the 
Jendrassicmaneuver.if the reflex is absent even in the face of the 
Jendrassicmaneuver, the reflex is considered absent . 
 
IV. Monofilament Testing : For this examination , it is important that the 
patient’s foot be supported . the filament should be applied on the 
dorsum of the great toe midway between the nail fold and DIP joint. 
The filament is applied perpendicularly and briefly with an even 
pressure. When the filament bends, the force of 10gms has been 
applied. The patient whose eyes are closed is asked to respond yes if 
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he/she feels the filament. Eight correct response out of 10 is 
considered normal , one to seven responses indicates reduced 
sensation and no correct answers translates into absent sensation. 
 
10g SEMMES WEINSTEIN MONOFILAMENT 
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MATERIALS AND METHODS 
DESIGN 
Cross sectional study 
STUDY POPULATION 
This study on the prevalence of distal sensory peripheral neuropathy will 
be done in patients attending Outpatient clinic in Government Vellore Medical 
College. 
SAMPLE SIZE  
216 
STUDY PERIOD 
September 2015 to August 2016 
INCLUSION CRITERIA 
 Prediabetic population of age more than 30 years old 
EXCLUSION CRITERIA 
1. Patient denying consent. 
2. Type 1 Diabetes Mellitus patient. 
3. Pregnancy 
4. Patient with other known cause of peripheral neuropathy such as 
a. Hypothyroidism 
b. Vitamin B12 deficiency 
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c. Alcohol 
d. Uremia 
e. Tubuerculosis 
f. HIV 
g. Patients on drugs having peripheral neuropathy as established 
toxicity . 
 
METHODOLOGY 
After prior Institutional Ethical clearance and obtaining informed 
consent, the participants satisfying inclusion criteria were asked detailed 
history  and clinical examination was performed according to the well designed 
proforma cited below . Venous blood was drawn for fasting blood glucose 
levels, HbA1c levels, serum cholesterol and triglycerides. Height, weight and 
waist circumference of the individual patient was measured and BMI was 
calculated . Presence of peripheral neuropathy was assessed by validated MNSI 
(Michigan Neuropathy Screening Instrument) scoring system.  
ETHICAL CLEARANCE: 
This study was approved by the ethical committee of Government 
Vellore Medical College , Vellore . 
STATISTICAL ANALYSIS : 
Statistical analysis was done by using SPSS 16 software. Quantitative 
data was expressed in mean , median , mode and standard deviation . 
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qualitative data was expressed by CHI-SQUARE test. The difference was 
considered statistical significant if the p value was less than 0.05 
 
OPERATIONAL GUIDELINES 
Diagnosis of Pre-Diabetes was based on ADA (American Diabetic 
Association ) guidelines : 
a. Fasting blood sugar  ≥ 100 to 125 mg/dl 
Or 
b. 2 hour plasma glucose≥ 140 to 199 mg/dl 
Or 
c. HbA1c levels ≥ 5.7 % to 6.4% 
 
BLOOD PRESSURE: 
Normal     - Systolic BP <120 mm Hg and  
     Diastolic BP < 80 mm Hg 
Prehypertension   –   Systolic BP 120-139 mm Hg and/or  
Diastolic BP 80-89 mm Hg 
Systemic Hypertension - Systolic BP ≥140 mm Hg and/or 
Diastolic BP ≥90 mm Hg 
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BODY MASS INDEX : 
BMI was calculated using the formula, 
BMI = weight in kg/ height in m2 
The BMI values were interpreted based on the Indian standards 
  BMI 18-22.9 kg/m2  = normal 
  BMI 23-24.9 kg/m2  = overweight 
  BMI ≥ 25 kg/m2  = obesity 
DYSLIPIDEMIA : 
Total cholesterol  ≥ 200 mg/dl 
Triglycerides         ≥ 150 mg/dl 
 
WAIST CIRCUMFERENCE : 
Males  – ≥ 90 cms 
Females  - ≥ 80 cms 
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RESULTS AND ANALYSIS 
AGE 
The mean age of the study subjects was 56.3 years . Most of the patients 
belonged to the age group 50-59 years. 
SEX 
Out of 216 cases , 110 (50.93%) were male and 106 (49.07%) were 
female. Male to female ratio was 1.04 :1.  
TABLE 1 
AGE AND SEX DISTRIBUTION 
AGE 
(IN YRS) 
MALE FEMALE TOTAL PERCENTAGE(%) 
<40 4 5 9 4.2 
40-49 28 20 48 22.2 
50-59 41 39 80 37 
60-69 29 32 61 28.2 
≥70 8 10 18 8.3 
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9 patients (4.2%) in the study were in the age group of <40 years. Of 
these 4 were male and 6 were female. 48 patients (22.2%) were in the age 
group between 40-49 years. Of these 28 were male and 20 were female. 80 
patients (37%) were in the age group between 50-59 years. Of these 41 were 
male and 39 were female. 61 patients (28.2%) were in the age group between 
60-69 years. Of these 29 were male and 32 were female. 18 patients (8.3%)  
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were in the age group of ≥ 70 years. Of these 8 were male and 10 were female. 
Most of the patient belonged to age group between 50-59 years. 
PREVELENCE OF DIABETIC PERIPHERAL 
NEUROPATHY 
TABLE 2  
DISTRIBUTION OF DPN IN THE STUDY POPULATION 
 
 
DPN 
TOTAL 
PRESENT ABSENT 
MALE 30(27.27%) 80 110 
FEMALE 31(29.25%) 75 106 
TOTAL 61(28.24%) 155 216 
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 In our study , 61 subjects had peripheral neuropathy according to MNSI 
score of ≥3 . Out of these 61 patients 30 were male and 31 were female. Out of 
155 prediabetics who were not having diabetic peripheral neuropathy , 80 were 
male and 75 were female. The prevalence of Diabetic peripheral neuropathy in 
the study population was 28.24% .From the above X2=  0.104 and p value was 
0.747 (<0.05)   ; hence statistically insignificant. 
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TABLE 3 
DISTRIBUTION OF DPN AND AGE 
 
 
 
AGE 
(In years) 
DPN 
 
TOTAL PRESENT ABSENT 
<40 0 9 9 
40-49 6 42 48 
50-59 21 59 80 
60-69 18 43 61 
≥70 16 2 18 
TOTAL 61 155 216 
 
Among subjects who had DPN 6 (9.8 percent) were in the age group 
between 40 to 49 ;  21(34.4 percent ) were between 50-59 ; 18 (29.5 percent) 
were between 60-69 ; and 16 (26.2 percent) were more than 70 years old. Most 
of the patients belonged to age group between 50 and 59 . However the 
prevalence of peripheral neuropathy in patients aged more than 70 was very 
high (88.9 percent) 
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In this table the relationship between DPN and Age ≥70 was calculated.Using 
Pearson Chi-Square test , X2was 33.3 ; p value was <0.05. Prevalence of DPN 
in person aged more than 70 years was statistically significant. 
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TABLE 4 
DISTRIBUTION OF HYPERTENSION IN THE STUDY 
POPULATION  
 SHT NORMAL BP 
MALE 33 77 
FEMALE 32 74 
TOTAL 65(30.10%) 151 
 
Out of 216 subjects, 65 (30.10%) were diagnosed to have systemic 
hypertension . The prevalence of systemic hypertension in the study population 
was 30.1 % . Mean systolic BP of the study population was 128 mm of Hg. 
Mean Diastolic BP of the study population was 81 mm of Hg. 
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TABLE 5 
DISTRIBUTION OF DPN AND SHT 
 
 
 
DPN 
 
TOTAL PRESENT ABSENT 
SYSTEMIC HT 32(52.5%) 33 (21.29%) 65 
NORMAL BP 29 122 151 
TOTAL 61 155 216 
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Out of 61 patients with Diabetic Peripheral Neuropathy 32 patients had 
Systemic Hypertension . In 155 subjects without DPN 33 had Systemic 
Hypertension. The prevalence of Systemic Hypertension in subjects with DPN 
was 52.5 %. Out of 32 patients 17 were male and 15 were female. The 
prevalence of systemic hypertension in subjects without DPN was 21.29 %.  
 
 
From the above table X2 = 20.214 and the P value was 0.001; thus 
statistically highly significant . 
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TABLE 6 
DISTRIBUTION OF BODY MASS INDEX IN THE 
STUDY POPULATION 
 
BMI MALE FEMALE TOTAL PERCENTAGE 
<18 4 3 7 3% 
18-22.9 45 47 92 43% 
23-24.9 21 25 46 21% 
≥25 40 31 71 33% 
 
The average BMI of the study population was 24.2  . Out of 216 study 
population 92 patients were having normal BMI .7 (3%)patients were 
underweight . 46 (21 %) were overweight and 71(33%) were obese .  
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TABLE 7 
DISTRIBUTION OF DPN AND  BMI 
 
BMI 
DPN TOTAL 
PRESENT ABSENT 
<18 0(0%) 7(4.51%) 7 
18-22.9 18(29.5%) 74(47.74%) 92 
23-24.9 5(8.20%) 41(26.45%) 46 
≥25 38(62.30%) 33(21.29%) 71 
TOTAL 61 155 216 
 
 
From the above table , 38 out of 61 subjects with DPN were obese and 
similarly out of 155 subjects without DPN 33 were obese. The prevalence of  
obesity in subjects with DPN was 62.30 % and that of subjects without DPN 
was 21.30 %. X2 = 33.355 and p value was 0.001 ; hence statistically highly 
significant . 
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TABLE 8 
DISTRIBUTION OF HBA1C IN THE STUDY 
POPULATION 
HbA1c MALE FEMALE TOTAL PERCENTAGE 
≤5.5 32 24 56 26.93% 
5.6-6 46 47 93 43.06% 
6.1-6.6 32 35 67 31.02% 
TOTAL 110 106 216  
 
The average HbA1c of the study population was 5.8% . In the study 
population 56 (25.93 %) subjects had HbA1c levels ≤ 5.5 . Among these 32 
were male and 24 were female . 93 subjects (43.06 percent) had HbA1c 
between 5.6 and 6. Among them 46 were male and 47 were female . 67 patients 
(31.02%) had HbA1c levels ≥6.1 . Among them 32 were male and 35 were 
female. Most of the patients belonged to the HbA1c level between 5.6 to 6. 
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TABLE 9 
DISTRIBUTION OF DPN AND HBA1C 
 
 
 
HbA1c 
 
DPN 
 
TOTAL PRESENT ABSENT 
≤5.5 3(4.92%) 53(34.19%) 56 
5.6-6 22(36.07%) 71(45.81%) 93 
6.1-6.4 36(59.02%) 37(23.87%) 67 
Total 61 155 216 
 
 From the above table , among subjects with DPN , 3 (4.92%) had 
HbA1c less than 5.5, 22 (36.07%) had HbA1c levels between 5.6 to 6, 36 
(59.02%) had HbA1c levels between 6.1-6.4% . Most of the subjects with DPN 
belonged to the group where the HbA1c levels were between 6.1-6.4%. The 
prevalence was 59.02 %. Among subjects without DPN 53 (34.19%) had 
HbA1c below 5.5 ,71(45.81%) had HbA1c between 5.6 and 37 (23.87%) . The 
relationship between DPN and HbA1c more than 6.1 was plotted . X2 = 30.881    
and p value was less than 0.001 ; thus statistically highly significant . 
 
54 
 
 
 
 
 
 
HBA1C <5.5
HBA1C 5.6-6
HBA1C 6.1-6.4
0
10
20
30
40
50
60
70
80
DPN + DPN -
3 
53 
22 
71 
36 
31 
N
O
. 
O
F
 P
A
T
IE
N
T
S
 
DIABETIC PERIPHERAL NEUROPATHY 
CHART 9 
DPN AND HBA1C 
HBA1C <5.5 HBA1C 5.6-6 HBA1C 6.1-6.4
55 
 
TABLE 10 
DISTRIBUTION OF SERUM CHOLESTEROL IN STUDY 
POPULATION 
 SERUM CHOLESTEROL 
<200 mg/dl ≥200mg/dl 
MALE 86 24 
FEMALE 82 24 
TOTAL 168 48(22.2%) 
 
Out of 216 subjects, 48 had serum cholesterol level more than 200 mg/dl 
. Among these subjects 24 were male and 24 were female. The prevalence of 
hypercholesterolemia in the study population was 22.2 percent.  
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TABLE 11 
DISTRUBUTION OF DPN AND SERUM CHOLESTEROL 
 
 
SERUM 
CHOLESTEROL 
(mg/dl) 
DIABETIC PERIPHERAL 
NEUROPATHY 
 
TOTAL 
PRESENT ABSENT 
≥200 39(63.9%) 9(5.8%) 48(22.2%) 
<200 22 146 168 
TOTAL 61 155 216 
 
In subjects with DPN , 39  (63.9%) had serum cholesterol level of  ≥ 200 mg/dl 
. The prevalence of hypercholesterolemia in patients with Peripheral 
Neuropathy was 63.9 percent and in patients with normal serum cholesterol 
was 5.8 percent. Mean cholesterol level of the subjects with peripheral 
neuropathy was 214.75 mg/dl and that of subjects without peripheral 
neuropathy was 169.61 mg/dl. 
 From the above X2=  85.573     and the p value was <0.001 ; thus 
statistically highly significant . 
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TABLE 12 
DISTRIBUTION OF SERUM TRIGLYCERIDES IN 
STUDY POPULATION 
 SERUM TGL 
<150 mg/dl ≥150mg/dl 
MALE 96 14 
FEMALE 89 17 
TOTAL 185 31(14.4%) 
 
From the above table, 31 subjects had hypertriglyceridemia ( 
≥150mg/dl). Of these 14 were male and 17 were female. The prevalence of 
hypertriglyceridemia in the study population was 14.4 % . The mean TGL of 
the study population was 135.11 mg/dl 
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TABLE 13 
DISTRIBUTION OF DPN AND SERUM TGL 
 
TRIGLYCERIDES 
(mg/dl) 
 
DIABETIC PERIPHERAL 
NEUROPATHY  
TOTAL 
PRESENT ABSENT 
≥150 23(37.7%) 8 (5.2%) 31(14.4%) 
<150 38 147 185 
TOTAL 61 155 216 
 
Mean TGL levels in subjects with DPN was 146.95 mg/dl and in 
subjects without DPN was 130.45 mg/dl. In subjects with Peripheral 
Neuropathy 23 out of 61 patient had increased TGL levels . The prevalence of 
hypertriglyceridemia in peripheral neuropathy was 37.7 percent. Out of 155 
subjects who did not have peripheral neuropathy , only 8 patients had 
hypertriglyceridemia . The prevalence was 5.2 percent. From the above table 
X2 =  79.489 and p value was less than 0.001 ; thus statistically highly 
significant.  
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TABLE 14 
DISTRIBUTION OF DYSLIPIDEMIA IN THE STUDY 
POPULATION 
 
 DYSLIPIDEMIA 
NORMAL 
LIPID 
PROFILE 
TOTAL 
MALE 26 84 110 
FEMALE 24 82 106 
TOTAL 50(23.26%) 166(76.85%) 216 
 
 
Out of 216 study population , 50 subjects had Dyslipidemia . 26 were 
male and 24 were female. 166 subjects had normal lipid profile . 84 were male 
and 82 were female. The prevalence of Dyslipidemia in the study population 
was 23.26% . 
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TABLE 15 
DISTRIBUTION OF DYSLIPIDEMIA  AND DPN 
 
 
 
DYSLIPIDEMIA 
DIABETIC PERIPHERAL 
NEUROPATHY  
TOTAL 
PRESENT ABSENT 
PRESENT 39(63.93%) 11(7.10%) 50(23.26%) 
ABSENT 22 144 166 
TOTAL 61 155 216 
 
 From this table X2 =    79.489  and p value was less than 0.05 ; thus 
statistically highly significant . 
 Out of 61 subjects who had DPN , 39 subjects (63.93%) had 
dyslipidemia. Out of 155 subjects without DPN , only 11 subjects (7.10%) had 
dyslipidemia.  The prevalence of Dyslipidemia in subject with DPN was 63.93 
% and the relationship between DPN and Dyslipidemia is statistically 
significant. 
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TABLE 16 
DISTRIBUTION OF SMOKING IN THE STUDY 
POPULATION 
 SMOKERS NON SMOKERS 
MALE 33 77 
FEMALE 2 104 
TOTAL 35(16.2%) 181(83.77%) 
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Out of 216 study subjects , 35(16.2%)  were smokers and 181(83.77%)  
were non smokers. Out of 35 smokers , 33 were male and 2 were females. Out 
of 181 non smokers 77 were male and 104 were female. The prevalence of 
smokers in the study population was 16.2 % . 
TABLE 17 
DISTRIBUTION OF SMOKING AND DPN 
 
 
 
SMOKING 
 
DIABETIC PERIPHERAL 
NEUROPATHY 
 
TOTAL 
PRESENT ABSENT 
YES 17(27.87%) 18(11.6%) 35(16.2%) 
NO 44 137 181 
TOTAL 61 155 216 
 
In subjects diagnosed to have peripheral neuropathy 17 were smokers 
and 44 were non smokers . The prevalence of smokers in DPN was 27.87%. 
Among subjects without DPN 18 were smokers and 137 were non smokers. 
The prevalence of smokers in subjects without DPN was 11.6% .From the 
above table X2 =   8.519      and the p value was 0.004 ; thus statistically 
significant. 
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TABLE 18 
DISTRIBUTION OF WAIST CIRCUMFERENCE IN THE 
STUDY POPULATION 
 
ABNORMAL WAIST 
CIRCUMFERENCE 
NORMAL WAIST 
CIRCUMFERENCE 
MALE 32(29.09%) 78 
FEMALE 37(34.91%) 69 
TOTAL 69 (31.94%) 147 
 
The average waist circumference of the study population was 82.58 cms. 
The average waist circumference of the males was 85.62 cms and that of 
females was 79.33 cms.Among the study population 69 (31.94 %) subjects had 
abnormal waist circumference and 147 (68.06 %) subject had normal waist 
circumference.  32 were male and 37 were female .. The prevalence of 
abnormal waist circumference among males were 29.09 %  and 34.91 % in 
females. The average waist circumference of males was 85.63 % and that of 
females was 79.42 % . 
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TABLE 19 
DISTRIBUTION OF WAIST CIRCUMFERENCE  AND 
DPN 
 
 
 
ABNORMAL 
WAIST 
CIRCUMFERENCE 
 
DIABETIC PERIPHERAL 
NEUROPATHY 
 
TOTAL 
PRESENT ABSENT 
YES 32(52.46%) 37(23.87) 69(31.94%) 
NO 29 118 147 
TOTAL 61 155 216 
 
Out of 61 subjects with DPN 32 (17 male and 15 female ) had abnormal 
waist circumference . Out of 155 subjects without DPN, 37 had abnormal waist 
circumference . The prevalence of abnormal waist circumference in subjects 
with peripheral neuropathy was 52.46 % and the prevalence of abnormal waist 
circumference in subjects without peripheral neuropathy was 23.87%. 
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 From the above table X2 =      12.614    and P value was <0.05 ; hence 
statistically highly significant correlation between abnormal waist 
circumference and DPN. 
 
 
ABN WAIST CIRCM
NORMAL WAIST CIRC
0
20
40
60
80
100
120
DPN + DPN -
32 
37 
29 
118 
N
O
. 
O
F
 P
A
T
IE
N
T
S
 
DIABETIC PERIPHERAL NEUROPATHY 
CHART 19 
DPN AND WAIST CIRCUMFERENCE 
ABN WAIST CIRCM NORMAL WAIST CIRC
73 
 
DISCUSSION 
 
GENERAL CHARACTERISTICS 
 
 This study involved a total of 216 subjects of which 110(50.93%) were 
males and 106(49.07%) were females. Most of the subjects were in the age 
group 50-59 years. The mean age of the study population was 56.3 %.  
 
PREVALENCE OF DIABETIC PERIPHERAL NEUROPATHY 
 Among the study population 61 subjects had DPN . The prevalence of 
DPN in the study population was 28.24 %. Out of these 61 subjects 30 were 
male and 31 were female. Though the prevalence of DPN is slightly higher in 
female subjects , it was not statistically not significant ( X2 =0.104 and p value 
0.747) . Hence according to our study there is no sex difference in the 
prevalence of DPN in pre-diabetic subjects. Among subjects with DPN most of 
them belonged to the age group 50-59 (34.4%). However the prevalence of the 
DPN in the age group >70 years was very high (88.9 %) and statistically 
significant (X2 =33.3 and p value was <0.05) 
 In a study conducted by Dan Ziegler et al , the prevalence of peripheral 
neuropathy was 28.0 % in diabetic subjects , 13% in those with IGT , 11.3% in 
those with IFG . 30 
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In a similar study conducted by Papanas et al it was estimated that the 
prevalence of neuropathy in Pre-diabetics was around 11-25%. 31 
In another similar study conducted by Lee CC et al the prevalence of 
DPN in pre-diabetics was 49 % which was high compared to our study .33 
In the indianpopulation , a study was conducted by Meena et al which 
concluded that the prevalence was 32.8 % among subjects with impaired 
glucose tolerance.32 
 
DYSLIPIDEMIA  
In this study , the prevalence of dyslipidemia was 23.26 %. It was higher 
in subjects with DPN (63.93 %) than in subjects without DPN (7.10 %). P 
value. 
 
Mean total serum cholesterol was 214.75 mg/dl in subjects with DPN 
and 169.61 mg/dl in subjects without DPN . Prevalence of 
hypercholesterolemia was significantly higher in subjects with DPN (63.93 %) 
than in subjects without DPN (5.8 %)  . 
The prevalence of TGL in the study population was 14.4 %. Mean TGL 
value in subjects with DPN was 146.95 mg/dl and in subjects without DPN was 
130.45 mg/dl. Prevalence of hypertriglyceridemia was significantly higher in 
subjects with DPN (37.7 %).  
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In a similar study conducted by KATULANDA et. Al , the average total 
cholesterol level was 217.4 mg/dl in subjects with DPN and 217.1 mg/dl in 
subjects without DPN which was statistically insignificant 34. similarly mean 
TGL levels in subjects with DPN was 162.1 and in subjects without DPN was 
138.2 which was statistically significant . (p <0.05) 
HYPERTENSION 
The prevalence of systemic  hypertension in the study population was 
30.1 %. Mean systolic and diastolic BP were 128mm Hg and 81 mm Hg 
respectively . The prevalence of Systemic hypertension in subjects with DPN 
(52.5%)  was significantly higher  than in subjects without DPN (21.29%) . The 
p value was <0.05.  
According to a study conducted by Fargol Booya et Al , the prevalence 
of Systemic hypertension in patients with DPN was 41.8%  which was little 
higher than our study .35 
SMOKING  
 Among the study subjects , 35 people (16.2%) were smokers and 
181(83.77%) were non smokers. The prevalence of smokers was significantly 
higher in subjects with DPN (27.87%) than in subjects without DPN (11.6%). 
The p value was 0.004 (<0.05). 
In a similar study conducted by Dipika Bansal et al which was on 
prevalence of DPN in a cohort of diabetic subjects , the prevalence of smoking 
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in patients with DPN(12.4%) was statistically insignificant than in patients 
without DPN(13.3%) ( p<0.05) .36 
 
HBA1C 
 The average HbA1c of the study population was 5.8 %. The average 
HbA1c values of the subjects with DPN was 6.10 %. The prevalence of 
subjects whose HbA1c more than 6.0 was significantly higher in DPN 
subjects(59.02%) than in NON DPN (23.87%) subjects . p value was less than 
0.005. 
According to a study conducted by Solomon et al37, the subjects without 
diabetic peripheral neuropathy had good glycemic control than in subjects with 
peripheral neuropathy. 
 
BODY MASS INDEX 
 The average BMI of the study population was 24.2. out of 216 subjects 
71 were obese . The average BMI of the subjects with DPN was 26.8 %The 
prevalence of obesity in the study subject was 33 %. Among subjects with DPN 
38 were obese (BMI ≥25). The prevalence of obesity in subjects with DPN 
(62.30%) was signicantly higher than in subjects without DPN (p value <0.05). 
 In a similar study conducted by Christine Lee et al in PROMISE cohort , 
the average BMI of subjects with DPN was 30.7 and without DPN was 30.4 (p 
value >0.05). A prospective study on the prevalence and association of 
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Peripheral Neuropathy in Indian Diabetic patients by H.K Gill et al. did not 
find a statistical significant correlation between obesity and peripheral 
neuropathy .38 
WAIST CIRCUMFERENCE 
 The mean waist circumference of the study population was 82.58 cms. 
The mean waist circumference of the males were higher than in females . The 
prevalence of patients with  increased waist circumference was significant 
higher in subjects with DPN than in patients without DPN (p value <0.005). 
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CONCLUSION 
 
1. Peripheral Neuropathy is equally common in both diabetic and pre-
diabetic individual 
2. It is more prevalent in elderly pre-diabetic individuals of age more 
than 70 years . Both males and females are equally affected ; there is 
no sex predilection for the occurrence of peripheral neuropathy 
3. Hypertensive individuals are affected more than non hypertensives. 
4. There is strong relationship between obesity and peripheral 
neuropathy in pre-diabetic indivuduals. 
5. Prevalence of dyslipidemia is higher in pre-diabetic people with 
peripheral neuropathy . 
6. People with pre-diabetics who have peripheral neuropathy have higher 
HbA1c values . 
7. Smokers have higher prevalence of peripheral neuropathy among pre-
diabetics. 
Lastly since the prevalence of peripheral neuropathy is high even in pre-
diabetic population , my study emphasises the need for the early 
diagnosis of peripheral neuropathy in people who are at high risk for 
developing diabetes and to screen for the possible associated risk factors. 
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1 LEELAVATHY 49 F 132 80 N 96 155 5.2 147 59 27.3 NO 156 134 0 
 
90 
 
2 MALLIKA 45 F 118 76 N 92 134 5.7 157 58 23.5 NO 162 144 0 
 
78 
 
3 RAMESH 54 M 134 82 N 104 145 5.8 176 71 22.9 NO 201 122 3 Y 82 Y 
4 AMBIGA 34 F 108 68 N 80 148 5.2 166 59 21.4 NO 132 131 0 
 
88 
 
5 NIRMALA 78 F 156 94 Y 122 186 6.2 162 54 20.6 NO 230 165 5 Y 76 Y 
6 DEIVANAI 68 F 138 86 N 115 146 5.9 151 69 30.3 NO 224 130 3 Y 76 Y 
7 BALAJAMMAL 41 F 120 70 N 93 177 5.2 170 69 23.9 NO 214 155 0 
 
102 Y 
8 KALAMBASHA 46 M 124 86 N 91 133 5.9 171 60 20.5 NO 177 129 0 
 
86 
 
9 CHINNADURAI 58 M 130 78 N 111 198 6.4 180 71 21.9 NO 165 141 1 
 
82 
 
10 GOPI 50 M 122 90 N 88 154 5.6 168 54 19.1 NO 145 127 2 
 
75 
 
11 MANONMANI 52 F 134 70 N 112 164 6.2 155 81 33.7 NO 214 172 3 Y 84 Y 
12 ANBALAGAN 49 M 150 86 Y 110 136 5.1 188 77 21.8 YES 186 140 0 
 
102 
 
13 NILAVAZHAGI 39 F 102 70 N 82 144 5.8 166 69 25.0 NO 230 156 0 
 
94 Y 
14 NAAGAMANI 61 F 122 76 N 107 155 5.6 149 45 20.3 NO 192 145 0 
 
70 
 
15 RAMESH 44 M 120 80 N 98 166 6 165 67 24.6 YES 174 139 1 
 
87 
 
16 ARJUNAN 44 M 124 86 N 120 178 5.5 170 61 21.1 NO 155 142 1 
 
80 
 
17 JAGADEESAN 59 M 140 86 Y 98 132 6.2 162 56 21.3 NO 198 141 2 
 
87 
 
18 PANDIYAN 67 M 144 92 Y 112 198 6.6 167 93 33.3 YES 269 152 3 Y 104 Y 
19 KALYANASUNDARAM 71 M 154 100 Y 100 164 6.2 165 73 26.8 YES 211 160 3 Y 94 Y 
20 PAUL PRAVEEN 43 M 108 70 N 94 126 5.8 172 66 22.3 YES 143 147 1 
 
83 
 
21 VAIDIYALINGAM 46 M 124 80 N 101 177 5.8 165 47 17.3 NO 166 123 1 
 
80 
 
22 KANNAN 49 M 112 72 N 124 166 6.1 165 59 21.7 YES 230 122 4 Y 91 Y 
23 DIVYA 50 F 118 76 N 96 134 5.7 142 45 22.3 NO 163 120 0 
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24 RANJANI 54 F 114 82 N 122 180 6.5 157 78 31.6 NO 202 119 3 Y 84 Y 
25 RAMAN 56 M 130 74 N 104 145 5.2 170 69 23.9 NO 245 163 2 
 
82 Y 
26 RANJITH 42 M 112 70 N 106 134 4.9 173 56 18.7 NO 132 118 0 
 
67 
 
27 PRABHAKARAN 44 M 124 78 N 117 165 5.3 152 60 26.0 YES 145 117 0 
 
71 
 
28 SUNITHA 39 F 100 60 N 103 145 5.6 150 52 23.1 NO 133 143 0 
 
73 
 
29 VADIVAKKARASI 57 F 102 64 N 94 129 5.9 165 68 25.0 NO 178 100 0 
 
82 
 
30 RAVI 44 M 164 98 Y 98 166 5.8 182 83 25.1 YES 166 98 2 
 
90 
 
31 DAVID 51 M 144 100 Y 111 135 5.8 160 79 30.9 YES 177 104 3 Y 92 
 
32 MALLIGA 58 F 126 84 N 114 166 6.3 159 66 26.1 NO 214 124 4 Y 80 Y 
33 LILLY 62 F 116 102 Y 102 140 5.4 169 65 22.8 NO 234 178 3 Y 85 Y 
34 VASUKI 60 F 120 80 N 115 164 5.8 173 61 20.4 NO 132 114 0 
 
89 
 
35 KASIAMMAL 65 F 146 90 Y 111 134 5.6 165 65 23.9 NO 122 136 0 
 
79 
 
36 MANJULA 47 F 104 74 N 104 145 6.2 151 54 23.7 NO 145 144 1 
 
78 
 
37 SANTHANAM 53 M 100 68 N 119 189 6.3 173 95 31.7 NO 250 132 2 
 
92 Y 
38 RAMANI 53 F 164 102 Y 97 146 5.7 157 70 28.4 NO 166 140 2 
 
76 
 
39 GOMATHI 47 F 124 76 N 116 167 6.3 170 71 24.6 NO 145 130 1 
 
96 
 
40 BACKIYALAKSHMI 55 F 144 92 Y 112 145 6.2 152 79 34.2 NO 230 118 3 Y 84 Y 
41 MADHIAZHAGAN 59 M 168 88 Y 124 176 6.4 166 74 26.9 NO 189 105 3 Y 97 
 
42 AKILA 61 F 140 90 Y 105 195 5.9 166 56 20.3 NO 192 104 0 
 
78 
 
43 WELLINGTON 54 M 132 78 N 102 151 6 170 95 32.9 NO 209 222 4 Y 101 Y 
44 VALLIYAMMAL 66 F 134 78 N 109 140 5.8 157 45 18.3 NO 166 98 0 
 
78 
 
45 VARADHAN 55 M 120 80 N 108 161 6.2 178 68 21.5 YES 125 114 0 
 
85 
 
46 MUMTAJ 67 F 154 90 Y 100 142 5.4 155 53 22.1 NO 180 126 2 
 
85 
 
47 VADIVEL 61 M 140 78 Y 108 155 5.7 170 61 21.1 YES 198 128 1 
 
70 
 
48 MENAKA 59 F 144 92 Y 121 178 6.4 163 83 31.2 NO 240 156 3 Y 104 Y 
49 KAALEESHWARI 49 F 122 74 N 98 156 6.1 160 68 26.6 NO 166 140 0 
 
93 
 
50 YUVARAJ 56 M 130 80 N 107 165 5.3 169 59 20.7 NO 172 132 0 
 
86 
 
51 MUBEENA 66 F 126 84 N 101 171 6.1 160 54 21.1 NO 175 133 2 
 
77 
 
52 THANGARAJAN 40 M 144 92 Y 103 145 5.2 155 59 24.6 YES 145 124 1 
 
79 
 
53 JAYAKUMAR 57 M 152 88 Y 94 166 6.1 183 74 22.1 NO 132 134 4 Y 83 
 
54 KALAVATHY 69 F 126 78 N 120 174 6.4 150 72 32.0 NO 255 153 3 Y 104 Y 
55 AROKIYARAJ 74 M 156 100 Y 102 152 5.3 178 61 19.3 NO 166 117 5 Y 81 
 
56 ANNAKODI 69 F 102 68 N 114 173 6 145 56 26.6 NO 180 102 1 
 
86 
 
57 SARAVANAN 66 M 102 70 N 104 144 5.4 151 73 32.0 NO 182 94 2 
 
85 
 
58 KRISHNAN 65 M 132 80 N 118 160 6.2 163 63 23.7 YES 145 122 3 Y 92 
 
59 UDHAYAKUMAR 68 M 146 94 Y 117 141 5.9 174 62 20.5 YES 144 145 0 
 
92 
 
60 RAJAGANESH 52 M 140 84 Y 97 166 6 163 60 22.6 NO 187 155 0 
 
69 Y 
61 PARTHASARATHI 57 M 120 70 N 109 160 6.1 189 59 16.5 NO 165 134 2 
 
76 
 
62 RAJAMMAL 56 F 114 74 N 106 138 5.6 163 74 27.9 NO 201 163 3 Y 77 Y 
63 DURGA 58 F 150 90 Y 107 154 5.8 163 51 19.2 NO 234 177 3 Y 82 Y 
64 KANNIYAMMAL 67 F 134 88 N 111 140 5.4 150 65 28.9 NO 145 144 0 
 
90 
 
65 ANNIEPRINCY 66 F 112 76 N 102 150 5.2 165 59 21.7 NO 187 136 0 
 
78 
 
66 VIMALA 45 F 142 80 Y 90 160 5.9 167 59 21.2 NO 141 135 3 Y 77 
 
67 KARUNAKARAN 43 M 122 82 N 102 144 5.2 170 74 25.6 NO 180 138 1 
 
87 
 
68 VASANTHAMMAL 52 F 140 90 Y 109 189 6.2 156 56 23.0 NO 179 149 1 
 
80 
 
69 GIRITHARAN 59 M 126 86 N 121 163 6.2 159 61 24.1 NO 256 140 3 Y 91 Y 
70 SIVALINGAM 60 M 104 64 N 100 142 5.7 170 68 23.5 YES 162 135 0 
 
72 
 
71 CHINNAMMAL 60 F 146 96 Y 123 190 6.4 154 48 20.2 NO 145 111 3 Y 73 
 
72 BOOPALAN 66 M 142 96 Y 116 188 6.5 178 88 27.8 YES 287 159 3 Y 93 Y 
73 JOHN BASHA 57 M 124 88 N 102 145 4.9 173 69 23.1 NO 166 110 0 
 
88 
 
74 KASTHURI 55 F 128 80 N 103 155 5.1 157 65 26.4 NO 163 123 0 
 
77 
 
75 SUSEELA 54 F 130 74 N 104 160 5.6 168 44 15.6 NO 174 122 1 
 
66 
 
76 PONNULINGAM 42 M 108 70 N 100 156 5.8 189 73 20.4 NO 188 124 2 
 
91 
 
77 GOPIKA 81 F 140 100 Y 116 173 6.5 163 54 20.3 NO 255 144 4 Y 87 Y 
78 RAASIAMMAL 66 F 112 74 N 112 198 6.4 159 72 28.5 NO 152 145 4 Y 70 
 
79 MANIKANDAN 38 M 108 76 N 110 150 5.9 177 96 30.6 NO 157 107 0 
 
80 
 
80 PANDIRAJ 55 M 110 70 N 115 156 5.7 163 60 22.6 NO 156 108 2 
 
80 
 
81 CHINNASAMY 65 M 110 70 N 102 147 6 164 62 23.1 YES 163 126 2 
 
82 
 
82 MUTHU 44 M 146 90 Y 104 147 5.5 170 60 20.8 NO 178 130 0 
 
76 
 
83 KAAMATCHI 56 F 104 74 N 112 132 5.9 155 54 22.5 NO 188 114 0 
 
79 
 
84 JAGAN 76 M 148 80 Y 114 160 6.1 157 71 28.8 YES 265 189 3 Y 79 Y 
85 RENUGA 66 F 120 76 N 107 146 5.5 159 53 21.0 NO 145 128 2 
 
76 
 
86 RAAGAVAN 65 M 120 78 N 98 156 6.2 185 89 26.0 NO 163 126 2 
 
85 
 
87 RANGASAMY 52 M 118 82 N 112 149 5.6 183 81 24.2 NO 213 154 1 
 
90 Y 
88 DEVI 69 F 146 84 Y 100 146 6.5 154 59 24.9 NO 183 144 2 
 
92 
 
89 ANTHONY 63 M 150 90 Y 123 170 6.5 177 75 23.9 NO 164 145 3 Y 106 
 
90 AMUL 57 F 124 78 N 106 148 5.6 151 78 34.2 NO 290 190 3 Y 101 Y 
91 VENDA 58 F 114 80 N 111 187 6.1 153 57 24.3 NO 188 132 1 
 
68 
 
92 MEENAKSHI 80 F 142 96 Y 102 144 6 153 45 19.2 NO 267 133 3 Y 75 Y 
93 USHA 73 F 126 68 N 89 160 6.1 155 77 32.0 NO 232 192 3 Y 78 Y 
94 JALALUDEEN 66 M 134 80 N 94 143 5.9 173 70 23.4 NO 156 144 0 
 
88 
 
95 SRIRAM 69 M 160 78 Y 104 155 5.9 180 68 21.0 NO 166 122 0 
 
94 
 
96 SADAIYAN 61 M 124 86 N 120 190 6.4 170 91 31.5 NO 162 123 2 
 
99 
 
97 MURUGAN 57 M 112 68 N 121 146 6.2 176 65 21.0 YES 145 107 1 
 
86 
 
98 BABU 59 M 154 104 Y 107 156 5.5 169 59 20.7 YES 163 140 0 
 
82 
 
99 NATARAJAN 55 M 102 64 N 107 134 5.2 169 60 21.0 NO 182 140 0 
 
86 
 
100 KARTHIKEYAN 63 M 132 86 N 115 160 5.4 178 68 21.5 NO 174 122 1 
 
83 
 
101 SELVAKUMAR 67 M 150 100 Y 121 182 6.5 165 53 19.5 YES 216 132 5 Y 70 Y 
102 DEEPA 61 F 142 80 Y 100 132 5.1 145 48 22.8 NO 166 144 1 
 
77 
 
103 MANNU 54 F 110 70 N 103 140 4.9 150 53 23.6 NO 182 120 2 
 
90 
 
104 JAYABAL 45 M 118 78 N 112 165 5.8 177 63 20.1 NO 163 128 1 
 
95 
 
105 VELMURUGAN 46 M 122 84 N 101 149 5.3 171 64 21.9 NO 174 127 1 
 
86 
 
106 KATTABOMMAN 47 M 136 76 N 109 166 5.9 159 68 26.9 NO 166 133 0 
 
88 
 
107 MOTTAYAN 38 M 102 82 N 100 140 5.8 170 86 29.8 NO 150 132 0 
 
99 
 
108 MANIMEGALAI 86 F 156 98 Y 125 187 6.5 155 70 29.1 NO 247 172 3 Y 77 Y 
109 POOVARASI 72 F 112 80 N 120 174 6.3 156 59 24.2 NO 256 177 4 Y 76 Y 
110 CHINNAPONNU 63 F 144 78 Y 111 135 5.7 166 59 21.4 NO 140 100 1 
 
77 
 
111 SEETHA 61 F 126 70 N 120 190 5.6 166 60 21.8 NO 132 108 1 
 
69 
 
112 ANANDHAN 50 M 128 84 N 86 140 5.8 175 72 23.5 NO 133 96 2 
 
87 
 
113 PAARVATHIAMMAL 53 F 112 74 N 114 198 6.1 160 71 27.7 NO 188 122 3 Y 78 
 
114 DURAI 56 M 118 82 N 111 172 4.9 160 63 24.6 NO 166 144 0 
 
87 
 
115 PRAKASH 66 M 104 72 N 98 145 5.7 175 86 28.1 NO 212 135 0 
 
94 Y 
116 ANITHA 55 F 120 80 N 102 150 5.6 153 44 18.8 NO 145 125 0 
 
78 
 
117 MUTHUSAMY 68 M 170 110 Y 119 172 6.2 168 88 31.2 YES 199 129 3 Y 96 
 
118 SULTANA 46 F 140 92 Y 102 135 5.9 160 62 24.2 NO 160 134 2 
 
70 
 
119 VICTORIA 47 F 124 74 N 104 190 6.4 167 62 22.2 NO 166 133 1 
 
75 
 
120 FATHIMA 70 F 140 92 Y 112 156 5.9 155 62 25.8 NO 175 136 3 Y 76 
 
121 JUSTINE 72 M 150 94 Y 113 150 5.9 183 68 20.3 NO 174 144 0 
 
76 
 
122 MUNIYAMMA 66 F 118 72 N 109 164 6 153 40 17.1 NO 166 95 2 
 
67 
 
123 AMUDHA 74 F 154 82 Y 94 146 5.8 166 88 31.9 NO 244 199 6 Y 86 Y 
124 GUNALAN 76 M 138 74 N 102 140 5.7 171 106 36.3 NO 161 103 3 Y 112 
 
125 ARPUTHAM 55 F 102 78 N 105 140 5.7 156 58 23.8 NO 171 107 1 
 
67 
 
126 CHINNAPAYYAN 47 M 104 80 N 116 172 5.9 177 70 22.3 NO 178 144 1 
 
87 
 
127 DANIEL 56 M 120 82 N 104 145 5.3 191 78 21.4 NO 198 125 0 
 
97 
 
128 JOICE 59 F 136 84 N 117 171 6.5 159 72 28.5 NO 144 136 2 
 
92 
 
129 THILAGAVATHY 60 F 122 84 N 106 164 5.7 155 67 27.9 NO 155 114 2 
 
78 
 
130 ZEENATH BEGUM 67 F 132 76 N 112 139 5.8 155 78 32.5 NO 222 202 3 Y 88 Y 
131 ASHREEN 55 F 140 84 Y 121 190 6.2 160 59 23.0 NO 174 133 1 
 
73 
 
132 VINEETHA 52 F 108 66 N 114 164 5.9 162 55 21.0 NO 136 132 2 
 
74 
 
133 VIJAYARANGAN 61 M 124 88 N 106 174 6.1 170 80 27.7 NO 140 144 0 
 
78 
 
134 MONORAMA 39 F 114 72 N 121 196 6.3 166 63 22.9 NO 188 140 0 
 
84 
 
135 YASER ARAFAT 70 M 160 100 Y 90 146 6 165 53 19.5 NO 174 110 0 
 
84 
 
136 AROKIYASAMY 62 M 138 84 N 112 180 5.4 170 79 27.3 NO 188 151 1 
 
89 Y 
137 KRISHNAMOORTHY 65 M 110 72 N 106 136 5.4 168 64 22.7 NO 176 112 2 
 
80 
 
138 VADIVAMMA 66 F 126 82 N 125 185 6.5 155 54 22.5 NO 177 145 0 
 
93 
 
139 KANAGA 59 F 144 90 Y 112 145 6.1 149 51 23.0 NO 166 132 2 
 
78 
 
140 KAITHABEER 58 M 138 88 N 119 178 6.2 154 64 27.0 NO 222 114 4 Y 95 Y 
141 MANNU 64 M 142 96 Y 125 156 5.9 167 74 26.5 NO 302 140 4 Y 96 Y 
142 MANIMEGALAI 66 F 130 70 N 90 145 5.7 159 53 21.0 NO 144 149 0 
 
78 
 
143 DHAYALAN 50 M 144 102 Y 82 155 6 179 69 21.5 NO 165 132 0 
 
76 
 
144 NASEEMA 49 F 126 74 N 121 170 5.4 161 59 22.8 NO 188 147 0 
 
75 
 
145 DURARAJ 45 M 132 80 N 102 160 5.5 166 69 25.0 NO 177 130 0 
 
83 
 
146 SENTHIL KUMAR 65 M 110 68 N 114 140 5.7 159 59 23.3 NO 199 132 1 
 
88 
 
147 SUMATHI 55 F 130 68 N 115 139 5.2 153 56 23.9 NO 155 139 2 
 
67 
 
148 RAJENDIRAN 53 M 132 80 N 107 141 5.3 160 60 23.4 NO 145 140 2 
 
90 
 
149 JEBAMALAI 63 F 144 92 Y 103 165 5.9 154 52 21.9 NO 199 141 3 Y 77 
 
150 SAROJA 60 F 122 82 N 100 145 5.1 155 56 23.3 NO 185 145 1 
 
69 
 
151 VENDA 54 F 128 68 N 113 145 5.2 149 62 27.9 YES 219 212 3 Y 84 Y 
152 KUPPU 44 F 116 70 N 125 198 6.4 157 56 22.7 YES 144 132 3 Y 90 
 
153 NYANAMMAL 46 F 140 88 Y 116 165 5.8 153 49 20.9 NO 155 133 1 
 
72 
 
154 ARUMUGAM 43 M 108 68 N 93 146 5.7 169 56 19.6 NO 139 130 2 
 
72 
 
155 GOVINDASAMY 45 M 114 70 N 112 172 6.4 178 83 26.2 NO 170 132 3 Y 85 
 
156 HAVAMA 60 F 154 90 Y 103 145 5.7 155 53 22.1 NO 171 145 1 
 
77 
 
157 PATTAMAL 55 F 160 100 Y 106 150 6.2 156 54 22.2 NO 172 144 2 
 
77 
 
158 AMBUJAM 54 F 126 76 N 120 191 6.3 160 56 21.9 NO 185 140 0 
 
82 
 
159 SUBRAMANIAN 53 M 130 80 N 121 149 5.1 170 69 23.9 NO 188 135 0 
 
77 
 
160 TAAMARAISELVI 46 F 124 70 N 102 163 5.2 153 54 23.1 NO 165 134 0 
 
74 
 
161 RAMAN 47 M 136 76 N 116 174 5.9 185 71 20.7 YES 256 104 3 Y 80 Y 
162 SAAVITHRI 51 F 122 76 N 102 136 5.7 166 72 26.1 NO 180 114 1 
 
81 
 
163 SHANKAR 55 M 146 92 Y 114 174 6.2 165 74 27.2 NO 213 112 4 Y 91 Y 
164 SARALA 52 F 112 84 N 116 145 6.5 150 49 21.8 NO 155 128 0 
 
78 
 
165 UMAPATHI 60 M 114 78 N 101 174 6 169 67 23.5 NO 189 125 0 
 
84 
 
166 MANIVANNAN 38 M 104 72 N 90 145 5.8 167 64 22.9 YES 174 126 0 
 
75 
 
167 KANDHAN 39 M 112 80 N 112 134 5 173 68 22.7 YES 175 135 0 
 
68 
 
168 RAMAN 55 M 124 78 N 121 145 5.1 164 79 29.4 NO 160 140 1 
 
97 
 
169 RADHIKA 67 F 130 78 N 103 156 5.2 154 64 27.0 NO 162 136 2 
 
69 
 
170 PUSHPA 53 F 140 90 Y 114 180 5.4 166 56 20.3 NO 163 145 2 
 
71 
 
171 GYNANASEKARAN 59 M 124 78 N 120 166 5.9 156 54 22.2 NO 174 122 2 
 
83 
 
172 GOVINDHAN 46 M 112 86 N 102 141 5.7 167 72 25.8 NO 155 123 1 
 
88 
 
173 KASILINGAM 47 M 132 78 N 115 154 6.2 155 69 28.7 NO 195 140 1 
 
92 
 
174 ARUNKANNAN 70 M 148 84 Y 116 190 6.4 168 89 31.5 YES 165 136 3 Y 87 
 
175 SIVALINGAM 69 M 150 90 Y 121 160 6.5 177 90 28.7 NO 250 150 1 
 
90 Y 
176 VEERAN 60 M 136 86 N 122 163 5.8 165 59 21.7 NO 144 125 2 
 
75 
 
177 BHOOPATHI 57 M 114 76 N 102 144 5 189 56 15.7 NO 156 126 0 
 
88 
 
178 SRINIVASAN 54 M 112 78 N 107 165 5.2 159 56 22.2 NO 180 126 0 
 
89 
 
179 INDHUMATHI 50 F 124 86 N 112 182 5.8 167 55 19.7 NO 189 140 0 
 
71 
 
180 MRIDULA 49 F 104 68 N 103 174 5.9 160 60 23.4 NO 181 123 0 
 
73 
 
181 KIRUBAKARAN 48 M 108 70 N 98 145 6 165 61 22.4 NO 145 134 0 
 
84 
 
182 MALLIGA 52 F 112 84 N 111 140 5.2 155 41 17.1 NO 146 114 1 
 
66 
 
183 LAKSHMI 53 F 104 64 N 110 172 5.3 164 70 26.0 NO 203 140 1 
 
82 Y 
184 KIRUTHIKA 47 F 134 76 N 107 146 5.9 163 61 23.0 NO 147 114 1 
 
84 
 
185 VENDAMMAL 36 F 112 70 N 112 149 6.1 160 55 21.5 NO 187 126 0 
 
72 
 
186 MARIMUTHU 60 M 148 96 Y 121 165 6.2 164 87 32.3 YES 266 125 3 Y 96 Y 
187 SABAPATHY 51 M 124 68 N 105 193 5.4 160 57 22.3 NO 162 145 1 
 
78 
 
188 KOWSALYA 50 F 114 76 N 112 145 5.8 144 44 21.2 NO 174 132 0 
 
79 
 
189 HASEENA BEE 50 F 110 70 N 115 152 5.9 165 70 25.7 NO 159 133 0 
 
80 
 
190 RENGANAYAGI 66 F 136 96 N 106 162 5.9 170 69 23.9 NO 153 139 4 Y 84 
 
191 POOVAZHAGI 54 F 102 60 N 106 134 5 151 54 23.7 NO 170 136 1 
 
86 
 
192 BASHIR AHMED 55 M 140 90 Y 113 160 5.2 175 79 25.8 NO 166 134 2 
 
92 
 
193 LIONEL 49 M 126 82 N 121 169 5.8 180 72 22.2 NO 182 135 1 
 
76 
 
194 MARY JANE 66 F 136 84 N 125 170 6 181 64 19.5 NO 145 112 3 Y 75 
 
195 RAMMAYA 50 M 122 78 N 119 185 6.3 170 83 28.7 NO 289 187 3 Y 69 Y 
196 MAMTHA 78 F 146 86 Y 120 178 6.5 157 79 32.0 NO 274 166 4 Y 88 Y 
197 RUBIKA 73 F 160 90 Y 111 160 5.8 151 52 22.8 NO 178 124 4 Y 76 
 
198 SEENIAMMAL 60 F 112 78 N 102 138 5.2 163 63 23.7 NO 196 133 1 
 
77 
 
199 SAVITHA 43 F 140 90 Y 103 190 6.2 154 56 23.6 NO 155 140 2 
 
69 
 
200 RUCHIAMMAL 42 F 122 86 N 108 165 5.7 159 57 22.5 NO 166 141 0 
 
66 
 
201 SEVANATHAN 56 M 124 70 N 112 149 6 166 74 26.9 NO 145 142 3 Y 86 
 
201 GOPALAN 54 M 114 68 N 112 143 6 168 70 24.8 NO 173 109 1 
 
90 
 
203 RAVIVARMAN 64 M 140 90 Y 103 143 5.8 171 91 31.1 YES 260 159 2 
 
92 Y 
204 AMBIGAAMMAL 58 F 122 70 N 106 150 5.4 160 59 23.0 NO 165 110 0 
 
75 
 
205 HABIBUL BASHAR 44 F 140 90 Y 119 165 5.9 158 54 21.6 NO 185 111 0 
 
84 
 
206 ASHWIN 44 M 124 74 N 107 177 6 162 72 27.4 NO 250 188 3 Y 86 Y 
207 SUBBURAYAN 57 M 148 92 Y 102 178 6.2 164 59 21.9 YES 267 132 3 Y 78 Y 
208 SELVAMOORTHI 55 M 102 70 N 100 166 5.4 179 76 23.7 NO 170 130 0 
 
89 
 
209 REKHA 58 F 112 78 N 109 144 5.9 156 51 21.0 NO 144 145 1 
 
73 
 
210 LINGESHWARAN 64 M 126 80 N 109 140 5 176 52 16.8 NO 145 140 0 
 
74 
 
211 ROOPAVATHI 45 F 110 70 N 110 140 5.2 150 54 24.0 NO 189 135 1 
 
77 
 
212 ALLIMUTHU 44 M 130 84 N 118 161 5.3 156 57 23.4 YES 150 136 0 
 
75 
 
213 PANNEERSELVAM 83 M 154 110 Y 125 194 6.5 166 88 31.9 YES 300 234 6 Y 102 Y 
214 KANNAN 65 M 136 74 N 118 166 5.9 154 67 28.3 YES 174 122 3 Y 60 
 
215 PRABHAVATHI 44 F 100 70 N 118 165 6.2 166 59 21.4 NO 166 121 1 
 
69 
 
216 ABDUL KHADDAR 50 M 130 80 N 102 155 6.2 160 60 23.4 YES 189 119 2 
 
97 
  
PROFORMA 
 
 
1. NAME    :   
2. AGE     : 
3. SEX     :               MALE                      FEMALE     
4. OCCUPATION   : 
5. ADDRESS    : 
6. SYSTOLIC BP   : 
7. DIASTOLIC BP   :  
8. FASTING BLOOD GLUCOSE : 
9. POST PRANDIAL GLUCOSE : 
10. HBA1C    : 
11. HEIGHT  :  WEIGHT :   BMI: 
12. WAIST CIRCUMFERENCE  : 
13. SMOKING                                          :             YES                 
NO         
14. TOTAL CHOLESTEROL  : 
15. TRIGLYCERIDE   : 
16. MICHIGAN NEUROPATHY SCREENING  
INSTRUMENT (CLINICAL SCORE)  : 
 
  
PATIENT CONSENT FORM 
 
STUDY DETAIL:  
STUDY CENTRE: 
PATIENT’S NAME: 
PATIENT’S AGE: 
IDENTIFICATION NUMBER: 
I confirm that I have understood the purpose and procedure of the above study. 
I have the opportunity to ask questions and all my questions and doubts have been 
answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free 
to withdraw at any time without giving reason, without my legal rights being affected. 
I understand that the sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will not need 
my permission to look at my health records, both in respect of the current study and 
any further research that may be conducted in relation to it, even if I withdraw from 
the study I agree to this access. However I understand that my identity would not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this 
study. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological tests. 
 
Signature/thumb impression: 
Patient’s name and address:                                             Place:                              Date: 
Signature of the investigator: 
Name of the investigator:                                                  Place:                              
Date: 
 
  
  
